AbbVie Inc.
175.46
-1.28 (-0.72%)
At close: Jan 14, 2025, 3:59 PM
175.55
0.05%
After-hours Jan 14, 2025, 07:00 PM EST
undefined%
Bid 175.26
Market Cap 310.06B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) 2.86
PE Ratio (ttm) 61.35
Forward PE n/a
Analyst Buy
Ask 176.23
Volume 3,745,559
Avg. Volume (20D) 6,365,329
Open 176.61
Previous Close 176.74
Day's Range 174.14 - 176.78
52-Week Range 153.58 - 207.32
Beta undefined

About ABBV

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (...

Sector Healthcare
IPO Date Jan 2, 2013
Employees 50,000
Stock Exchange NYSE
Ticker Symbol ABBV

Analyst Forecast

According to 20 analyst ratings, the average rating for ABBV stock is "Buy." The 12-month stock price forecast is $205.5, which is an increase of 17.12% from the latest price.

Buy 85.00%
Hold 15.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

AbbVie Inc. is scheduled to release its earnings on Jan 31, 2025, before market opens.
Analysts project revenue of $14.81B, reflecting a 3.56% YoY growth and earnings per share of 2.98, making a 6.81% increase YoY.
4 weeks ago · Source
+2.18%
AbbVie shares are trading higher after Piper Sandl... Unlock content with Pro Subscription
1 month ago · Source
+3.04%
AbbVie shares are trading higher after Leerink Partners upgraded the stock from Market Perform to Outperform and announced a price target of $206.